DK1238282T3 - Fremgangsmåder til diagnose og behandling ved binding af P75/AIRM1 - Google Patents

Fremgangsmåder til diagnose og behandling ved binding af P75/AIRM1

Info

Publication number
DK1238282T3
DK1238282T3 DK00990705T DK00990705T DK1238282T3 DK 1238282 T3 DK1238282 T3 DK 1238282T3 DK 00990705 T DK00990705 T DK 00990705T DK 00990705 T DK00990705 T DK 00990705T DK 1238282 T3 DK1238282 T3 DK 1238282T3
Authority
DK
Denmark
Prior art keywords
cells
airm1
diagnosis
treatment
methods
Prior art date
Application number
DK00990705T
Other languages
English (en)
Inventor
Lorenzo Moretta
Roberto Biassoni
Alessandro Moretta
Maria C Mingari
Original Assignee
Univ Genova Biofisica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Genova Biofisica filed Critical Univ Genova Biofisica
Application granted granted Critical
Publication of DK1238282T3 publication Critical patent/DK1238282T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00990705T 1999-12-16 2000-12-11 Fremgangsmåder til diagnose og behandling ved binding af P75/AIRM1 DK1238282T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999FI000254A IT1307826B1 (it) 1999-12-16 1999-12-16 Metodo diagnostico per il riconoscimento di cellule mieloidi normali eleucemiche, ligandi utilizzati in detto metodo e formulazioni ad uso
PCT/EP2000/012509 WO2001044808A2 (en) 1999-12-16 2000-12-11 Methods of diagnosis and treatment by binding p75/airm1

Publications (1)

Publication Number Publication Date
DK1238282T3 true DK1238282T3 (da) 2009-07-27

Family

ID=11353132

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00990705T DK1238282T3 (da) 1999-12-16 2000-12-11 Fremgangsmåder til diagnose og behandling ved binding af P75/AIRM1

Country Status (9)

Country Link
US (1) US7384631B2 (da)
EP (1) EP1238282B1 (da)
JP (1) JP4890715B2 (da)
AT (1) ATE426812T1 (da)
AU (1) AU3009301A (da)
DE (1) DE60041883D1 (da)
DK (1) DK1238282T3 (da)
IT (1) IT1307826B1 (da)
WO (1) WO2001044808A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290031A4 (en) * 2000-05-24 2004-09-22 Smithkline Beecham Corp SIALOADHESIN FACTOR ANTIBODIES
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
JP4805633B2 (ja) 2005-08-22 2011-11-02 任天堂株式会社 ゲーム用操作装置
JP4262726B2 (ja) 2005-08-24 2009-05-13 任天堂株式会社 ゲームコントローラおよびゲームシステム
KR20180054639A (ko) 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
US20190023786A1 (en) * 2016-01-12 2019-01-24 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
EP3426688A1 (en) 2016-03-08 2019-01-16 Innate Pharma Siglec neutralizing antibodies
CN106831989A (zh) * 2017-01-04 2017-06-13 中国人民解放军南京军区军事医学研究所 人源抗唾液酸结合免疫球蛋白样凝集素‑7的抗体IgG及其应用
CA3066571A1 (en) 2017-07-10 2019-01-17 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
US11623954B2 (en) 2017-07-10 2023-04-11 Innate Pharma Siglec-9-neutralizing antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005783A1 (en) * 1987-01-28 1988-08-11 Ortho Pharmaceutical Corporation Immunosuppressive peptides and methods of use
WO1991009058A1 (en) * 1989-12-14 1991-06-27 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DE69719726T2 (de) * 1997-03-27 2003-10-16 Council Of Scientific And Industrial Research, New Delhi Verfahren zur Detektion von Leukämie

Also Published As

Publication number Publication date
US7384631B2 (en) 2008-06-10
EP1238282A2 (en) 2002-09-11
ITFI990254A0 (it) 1999-12-16
US20030077285A1 (en) 2003-04-24
ITFI990254A1 (it) 2001-06-16
JP2003517482A (ja) 2003-05-27
JP4890715B2 (ja) 2012-03-07
DE60041883D1 (de) 2009-05-07
IT1307826B1 (it) 2001-11-19
WO2001044808A2 (en) 2001-06-21
ATE426812T1 (de) 2009-04-15
EP1238282B1 (en) 2009-03-25
WO2001044808A3 (en) 2002-03-07
AU3009301A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
Urakawa et al. GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways
DK1238282T3 (da) Fremgangsmåder til diagnose og behandling ved binding af P75/AIRM1
NO2017039I1 (no) Bevacizumab - forlenget SPC
ATE293640T1 (de) Anti-vegf antikörper
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
Shimosaki et al. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma
Takahashi et al. RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin
Huang et al. Advanced gastric cancer patients with lymphoid stroma have better survival than those without
Brodská et al. Correlation of PD-L1 surface expression on leukemia cells with the ratio of PD-L1 mRNA variants and with electrophoretic mobility
Kumar et al. Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer
WO2004029287A3 (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2001098359A3 (en) Cyr61 as a target for treatment and diagnosis of breast cancer
FR2869416B1 (fr) Procede d'identification d'un ligand capable de moduler selectivement une cascade fonctionnelle impliquant une cible et ses applications pour le criblage a haut-debit de molecules d'interet.
WO2004083387A3 (en) Anti-ganglioside antibodies and methods of use
WO2023192289A3 (en) Anti-trophoblast cell surface antigen 2 (trop-2) antibodies
Liu Cutaneous Intravascular Conditions
Kummer et al. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways
WO2004019880A3 (en) Aw755252-interacting proteins and use thereof
FR2861178B1 (fr) Microplaques en elastomere porteuses de ligands reactifs, ainsi que leur procede de preparation